Structures by: Nangia A.
Total: 676
Carglumic Acid
C6H10N2O5
CrystEngComm (2015) 17, 28 5252
a=5.1179(8)Å b=12.2079(18)Å c=12.7508(19)Å
α=90.00° β=90.00° γ=90.00°
Carglumic Acid
C6H10N2O5
CrystEngComm (2015) 17, 28 5252
a=5.3615(5)Å b=15.8123(15)Å c=9.9631(9)Å
α=90.00° β=90.899(2)° γ=90.00°
Sulfacetamide4-aminopyridineSalt
C8H10N2O3S,C5H6N2
CrystEngComm (2014) 16, 26 5859
a=7.7413(7)Å b=17.8726(16)Å c=11.0065(10)Å
α=90.00° β=97.8790(10)° γ=90.00°
Sulfacetamide4,4'bipyridinecocrystal
C8H10N2O3S,C5H4N1
CrystEngComm (2014) 16, 26 5859
a=11.6469(9)Å b=10.4670(6)Å c=12.4421(9)Å
α=90.00° β=116.510(10)° γ=90.00°
SulfacetamideIsonicotinamidecocrystal
C8H10N2O3S,C6H6N2O,C6H6N2O
CrystEngComm (2014) 16, 26 5859
a=10.7667(4)Å b=9.7508(4)Å c=21.1014(7)Å
α=90.00° β=96.176(3)° γ=90.00°
SulfacetamideCaffeinecocrystal
C8H10N2O3S,C8H10N4O2
CrystEngComm (2014) 16, 26 5859
a=7.1821(6)Å b=30.430(3)Å c=8.8188(7)Å
α=90.00° β=107.6790(10)° γ=90.00°
SulfacetamideTheophyllinecocrystal
C8H10N2O3S,C7H8N4O2
CrystEngComm (2014) 16, 26 5859
a=8.6640(7)Å b=14.9675(13)Å c=15.3632(15)Å
α=110.234(2)° β=106.3650(10)° γ=97.2830(10)°
Furosemide potassuium salt monohydrate
C12H10ClN2O5SK.H2O
CrystEngComm (2014) 16, 22 4842
a=18.8967(10)Å b=11.1734(6)Å c=7.3056(4)Å
α=90.00° β=91.346(5)° γ=90.00°
Chlorodimethyl sulfonylhydrazone
C21H19ClN2O2S
CrystEngComm (2014) 16, 22 4681
a=22.305(2)Å b=12.0112(12)Å c=15.3336(15)Å
α=90.00° β=100.953(2)° γ=90.00°
Chlorodimethyl sulfonylhydrazone
C21H19ClN2O2S
CrystEngComm (2014) 16, 22 4681
a=11.726(5)Å b=15.488(7)Å c=22.317(10)Å
α=90.00° β=90.00° γ=90.00°
Fluorodimethyl sulfonylhydrazone
C21H19FN2O2S
CrystEngComm (2014) 16, 22 4681
a=11.939(2)Å b=15.261(3)Å c=21.322(4)Å
α=90.00° β=90.00° γ=90.00°
Tribromo sulfonylhydrazone
C19H13Br3N2O2S
CrystEngComm (2014) 16, 22 4681
a=23.334(8)Å b=11.594(4)Å c=15.600(5)Å
α=90.00° β=103.035(5)° γ=90.00°
Trichloro sulfonylhydrazone
C19H13Cl3N2O2S
CrystEngComm (2014) 16, 22 4681
a=22.655(4)Å b=11.6004(18)Å c=15.428(3)Å
α=90.00° β=101.926(3)° γ=90.00°
Olanzapine-Maleic acid 1:1
C17H21N4S,C4H3O4
CrystEngComm (2011) 13, 6 1759
a=10.852(5)Å b=13.748(7)Å c=13.879(7)Å
α=90.00° β=97.856(8)° γ=90.00°
Olanzapine-Maleic acid 1:2
C17H22N4S,2(C4H3O4)
CrystEngComm (2011) 13, 6 1759
a=8.518(3)Å b=9.804(4)Å c=16.210(6)Å
α=95.956(7)° β=97.945(7)° γ=107.789(7)°
ACM-PPZ
C4H12N22,2(C21H17ClNO6)
IUCrJ (2014) 1, 2 136-150
a=7.3994(15)Å b=25.6703(19)Å c=5.8254(17)Å
α=90.162(17)° β=98.598(16)° γ=98.315(19)°
C21H18ClNO6,C6H6N2O
C21H18ClNO6,C6H6N2O
IUCrJ (2014) 1, 2 136-150
a=21.7202(15)Å b=5.0077(14)Å c=11.8457(17)Å
α=90.00° β=93.954(13)° γ=90.00°
1:1 cocrystal of 4-hydroxybenzamide and bipyridine-N,N'-dioxide
C10H8N2O2,2(C7H7NO2)
Molecular Pharmaceutics (2007) 4, 3 417
a=5.692(4)Å b=9.482(6)Å c=10.751(7)Å
α=69.893(10)° β=84.232(10)° γ=84.969(10)°
C15H10Br2O
C15H10Br2O
Acta Crystallographica Section B (2000) 56, 6 1071-1079
a=5.7906(12)Å b=11.325(2)Å c=11.907(2)Å
α=115.67(3)° β=99.43(3)° γ=97.91(3)°
C15H10Cl2O
C15H10Cl2O
Acta Crystallographica Section B (2000) 56, 6 1071-1079
a=5.7082(1)Å b=11.3645(2)Å c=11.5167(1)Å
α=117.268(1)° β=99.257(1)° γ=96.726(1)°
C17H16O
C17H16O
Acta Crystallographica Section B (2000) 56, 6 1071-1079
a=6.8286(14)Å b=8.2407(16)Å c=12.658(3)Å
α=106.73(3)° β=98.71(3)° γ=101.39(3)°
C15H10Cl2O
C15H10Cl2O
Acta Crystallographica Section B (2000) 56, 6 1071-1079
a=5.7280(1)Å b=11.3620(2)Å c=11.5210(1)Å
α=117.240(1)° β=99.250(1)° γ=96.860(1)°
2,4,6-tris-(4-chlorophenoxy)-1,3,5-triazine tribromobenzene
C21H12Cl3N3O3,C6H3Br3
Acta Crystallographica Section B (2000) 56, 6 1080-1084
a=15.250(2)Å b=15.250(2)Å c=6.8149(14)Å
α=90.00° β=90.00° γ=120.00°
C21H12Cl3N3O3,C6H3Br3
C21H12Cl3N3O3,C6H3Br3
Acta Crystallographica Section B (2000) 56, 6 1080-1084
a=15.166(6)Å b=15.166(6)Å c=6.743(2)Å
α=90.° β=90.° γ=120.°
C27H20O
C27H20O
Acta Crystallographica Section B (2000) 56, 6 1071-1079
a=5.6413(3)Å b=10.2599(5)Å c=17.3238(9)Å
α=100.450(2)° β=97.790(2)° γ=95.477(2)°
2-Oxa-4-androsten-3,17-dione
C18H24O3
Acta Crystallographica Section B (2000) 56, 3 512-525
a=6.2321(3)Å b=9.9264(6)Å c=12.8120(8)Å
α=90.00° β=97.079(5)° γ=90.00°
2-Oxa-5-alpha-androstane-3,17-dione
C18H26O3
Acta Crystallographica Section B (2000) 56, 3 512-525
a=6.3180(4)Å b=6.4489(5)Å c=38.841(3)Å
α=90.00° β=90.00° γ=90.00°
17-Hydroxy-2-oxaandrost-4-ene-3-one
C18H26O3
Acta Crystallographica Section B (2000) 56, 3 512-525
a=14.241(2)Å b=9.4401(9)Å c=11.648(2)Å
α=90.00° β=90.00° γ=90.00°
6alpha-hydroxy-2-oxaandrost-4-ene-3,17-dione
C18H24O4
Acta Crystallographica Section B (2000) 56, 3 512-525
a=6.2214(7)Å b=12.0500(10)Å c=10.8880(10)Å
α=90.00° β=103.070(10)° γ=90.00°
6-hydroxy-2-oxa-5beta-androstane-3,17-dione
C18H26O4
Acta Crystallographica Section B (2000) 56, 3 512-525
a=6.3350(10)Å b=9.4820(10)Å c=27.245(6)Å
α=90.00° β=90.00° γ=90.00°
6,17-dihydroxy-2-oxaandrost-4-ene-3-one
C18H26O4
Acta Crystallographica Section B (2000) 56, 3 512-525
a=9.3361(7)Å b=9.6261(7)Å c=17.764(2)Å
α=90.00° β=90.00° γ=90.00°
2-Oxa-4-androsten-3,17-dione and 2-Oxa-6beta-hydroxy-4-androsten-3,17-dione
0.72(C18H24O4),0.28(C18H24O4)
Acta Crystallographica Section B (2000) 56, 3 512-525
a=6.2246(7)Å b=12.0140(10)Å c=10.9150(10)Å
α=90.00° β=103.090(10)° γ=90.00°
Tetrafluorohydroquinone
C6H2F4O2
Acta Crystallographica Section B (1999) 55, 6 1005-1013
a=6.5533(10)Å b=4.8848(10)Å c=10.148(2)Å
α=90.00° β=107.990(11)° γ=90.00°
Tetrabromohydroquinone
C6H2Br4O2
Acta Crystallographica Section B (1999) 55, 6 1005-1013
a=8.8907(2)Å b=4.73160(10)Å c=11.0612(3)Å
α=90.00° β=92.1670(10)° γ=90.00°
4-methylpyridine N-oxide Saccharin
C6H7NO,C7H5NO3S
Acta Crystallographica Section E (2006) 62, 6 o2283-o2284
a=14.960(3)Å b=12.330(3)Å c=7.3565(15)Å
α=90.00° β=100.24(3)° γ=90.00°
N,N'-Bis(4-biphenylyl)urea
C25H20N2O
Acta Crystallographica Section E (2003) 59, 6 o901-o902
a=8.9673(18)Å b=10.528(2)Å c=19.971(4)Å
α=90.00° β=90.00° γ=90.00°
N-(3-Pyridyl)urea
C6H7N3O
Acta Crystallographica Section E (2001) 57, 8 o719-o720
a=4.8558(10)Å b=8.1621(16)Å c=15.919(3)Å
α=90.00° β=92.16(3)° γ=90.00°
Tri-p-tolyltriazine
C24H21N3
Acta Crystallographica Section C (1999) 55, 4 698-700
a=15.005(3)Å b=20.397(4)Å c=6.3420(13)Å
α=90.00° β=90.00° γ=90.00°
2,6-Dibenzoyl-1,4-benzoquinone
C20H12O4
Acta Crystallographica Section C (1997) 53, 11 1653-1655
a=5.1928(5)Å b=20.405(2)Å c=29.517(3)Å
α=90.00° β=90.00° γ=90.00°
Trimethyl isocyanurate
C6H9N3O3
Acta Crystallographica Section C (1998) 54, 1 86-89
a=8.1420(10)Å b=13.3930(10)Å c=14.8220(10)Å
α=90.00° β=100.88(7)° γ=90.00°
17-Ethylenedioxyandrosta-1,4-diene-3,6-dione
C21H26O4
Acta Crystallographica Section C (1998) 54, 12 1894-1898
a=9.854(2)Å b=10.860(2)Å c=16.524(3)Å
α=90.00° β=90.00° γ=90.00°
5β-androstan-3,17-dione
C19H28O2
Acta Crystallographica Section C (1998) 54, 12 1898-1900
a=7.9475(5)Å b=8.3767(7)Å c=25.019(2)Å
α=90.00° β=90.00° γ=90.00°
Androst-4-ene-3,6,17-trione
C19H24O3
Acta Crystallographica Section C (1999) 55, 5 787-789
a=7.2842(6)Å b=13.4500(10)Å c=16.503(2)Å
α=90.00° β=90.00° γ=90.00°
4-(Triphenylmethyl)phenol-Triphenylphosphine Oxide(1/1)
C25H20O1,C18H15O1P1
Acta Crystallographica Section C (1999) 55, 9 1530-1533
a=9.3101(8)Å b=12.4840(11)Å c=14.7622(14)Å
α=89.988(2)° β=89.819(2)° γ=73.151(2)°
4-tosylsulphonylhydrazine
C7H10N2O2S
Acta Crystallographica Section E (2007) 63, 9 o3696-o3696
a=8.4166(8)Å b=5.6056(5)Å c=17.9484(17)Å
α=90.00° β=100.2600(10)° γ=90.00°
4-Biphenylylurea
C13H12N2O
Acta Crystallographica Section C (2001) 57, 6 777-778
a=9.3700(4)Å b=13.0330(5)Å c=17.5210(6)Å
α=90.00° β=90.00° γ=90.00°
Tris-(4-Tolyl)phenylmethane
C28H26
Acta Crystallographica Section C (2000) 56, 6 e259-e259
a=17.843(4)Å b=7.2015(14)Å c=33.176(7)Å
α=90.00° β=95.59(3)° γ=90.00°
3-Acetyl-1,2,6,7,12,12b-hexahydroindolo[2,3-a]quinolizin-2-one.
C17H16N2O2
Acta Crystallographica Section C (2001) 57, 1 97-99
a=8.169(16)Å b=12.841(3)Å c=14.772(3)Å
α=72.60(3)° β=75.54(3)° γ=72.64(3)°
3-Acetyl-4-oxo-6,7-dihydro-12H-indolo[2,3-a]quinolizine monohytrate
C17H14N2O2,H2O
Acta Crystallographica Section C (2001) 57, 1 97-99
a=7.307(15)Å b=9.405(2)Å c=10.989(2)Å
α=94.82(3)° β=108.84(3)° γ=90.96(3)°
3,4,5-Triiodotetraphenylmethane
C25H17I3
Acta Crystallographica Section C (2004) 60, 5 o331-o333
a=11.567(4)Å b=12.833(4)Å c=17.572(6)Å
α=108.031(6)° β=95.774(6)° γ=111.805(6)°
4,4-Diphenyl-6-(2,2-diphenyl-1-hydroxyethyl)-2-cyclohexen-1-one
C32H28O2
Acta Crystallographica Section C (2000) 56, 3 360-361
a=9.6111(9)Å b=11.5199(12)Å c=11.5621(12)Å
α=84.4580(10)° β=77.8290(10)° γ=74.1380(10)°
1,1,1-tris(4-hydroxyphenyl)methane--bipyridine (1/1)
C19H16O3,C10H8N2
Acta Crystallographica Section C (2003) 59, 8 o481-o484
a=26.483(5)Å b=34.102(7)Å c=10.483(2)Å
α=90.00° β=90.00° γ=90.00°
Tris(4-hydroxyphenyl)methane
C19H16O3
Acta Crystallographica Section C (2003) 59, 8 o481-o484
a=12.326(3)Å b=18.573(4)Å c=7.4961(15)Å
α=90.00° β=114.36(3)° γ=90.00°
2,2'-bis(4,4-diphenyl-2,5-cyclohexadienone)diselenide
C36H26O2Se2
Acta Crystallographica Section C (2000) 56, 1 123-124
a=17.4144(16)Å b=10.6767(10)Å c=15.2187(14)Å
α=90.00° β=90.00° γ=90.00°
2,3-Pyrazinedicarboxamide
C6H6N4O2
Acta Crystallographica Section C (2000) 56, 12 1512-1514
a=5.0250(3)Å b=7.0977(3)Å c=10.1196(5)Å
α=70.826(3)° β=81.868(3)° γ=81.163(3)°
Olanzapine
C17H20N4S
Acta Crystallographica Section C (2011) 67, 11 o461-o463
a=9.9130(8)Å b=16.5329(13)Å c=9.9992(8)Å
α=90° β=98.0230(10)° γ=90°
Febuxostat
C16H16N2O3S
Crystal Growth & Design (2013) 13, 7 3188
a=4.6756(4)Å b=17.6317(15)Å c=19.4992(15)Å
α=90.00° β=94.523(8)° γ=90.00°
Febuxostat-Nicotinamide
C16H16N2O3S,C6H6N2O
Crystal Growth & Design (2013) 13, 7 3188
a=6.9957(5)Å b=11.6356(11)Å c=13.7925(11)Å
α=102.644(7)° β=91.221(6)° γ=90.410(7)°
Febuxostat-PABA
C16H16N2O3S,C7H7NO2
Crystal Growth & Design (2013) 13, 7 3188
a=8.4227(9)Å b=11.1544(12)Å c=12.9327(14)Å
α=79.689(2)° β=81.524(2)° γ=68.220(2)°
Febuxostat-Acetamide
C16H16N2O3S,C2H5NO
Crystal Growth & Design (2013) 13, 7 3188
a=10.8516(4)Å b=23.6670(9)Å c=7.4362(4)Å
α=90.00° β=95.290(4)° γ=90.00°
Febuxostat-urea
C16H16N2O3S,CH4N2O
Crystal Growth & Design (2013) 13, 7 3188
a=7.6525(13)Å b=10.9684(18)Å c=12.261(2)Å
α=82.627(3)° β=71.822(3)° γ=69.866(3)°
DMSO solvate of N-(4-iodophenyl)-N'-(4'-nitrophenyl)-urea
C13H10IN3O3,C2H6SO
Crystal Growth & Design (2007) 7, 12 2675-2690
a=10.184(2)Å b=13.346(3)Å c=15.502(3)Å
α=66.82(3)° β=88.22(3)° γ=68.75(3)°
C20H18N2O2S
C20H18N2O2S
Crystal Growth & Design (2007) 7, 10 2047
a=9.8402(16)Å b=10.1297(16)Å c=10.5669(17)Å
α=117.517(2)° β=95.800(2)° γ=99.945(2)°
C20H16Br2N2O2S
C20H16Br2N2O2S
Crystal Growth & Design (2007) 7, 10 2047
a=11.4666(7)Å b=15.5694(9)Å c=22.2113(13)Å
α=90.00° β=90.00° γ=90.00°
C22H22N2O2S
C22H22N2O2S
Crystal Growth & Design (2007) 7, 10 2047
a=22.250(3)Å b=12.1201(15)Å c=15.2891(19)Å
α=90.00° β=100.538(2)° γ=90.00°
C20H16F2N2O2S
C20H16F2N2O2S
Crystal Growth & Design (2007) 7, 10 2047
a=12.3523(16)Å b=9.2366(12)Å c=16.492(2)Å
α=90.00° β=103.942(2)° γ=90.00°
C20H16Cl2N2O2S,0.5(C6H6)
C20H16Cl2N2O2S,0.5(C6H6)
Crystal Growth & Design (2007) 7, 10 2047
a=7.9816(16)Å b=11.793(2)Å c=13.501(3)Å
α=112.409(3)° β=106.616(3)° γ=93.815(3)°
C20H16Cl2N2O2S
C20H16Cl2N2O2S
Crystal Growth & Design (2007) 7, 10 2047
a=22.4996(17)Å b=11.4602(7)Å c=15.4310(9)Å
α=90.00° β=102.552(2)° γ=90.00°
C22H22N2O2S
C22H22N2O2S
Crystal Growth & Design (2007) 7, 10 2047
a=8.2971(5)Å b=39.758(3)Å c=5.9349(4)Å
α=90.00° β=97.2940(10)° γ=90.00°
C22.50H23ClN2O2S
C22.50H23ClN2O2S
Crystal Growth & Design (2007) 7, 10 2047
a=7.9174(18)Å b=11.701(3)Å c=13.248(3)Å
α=111.862(4)° β=107.198(4)° γ=93.619(4)°
Ammonium Cyclohexane-3cis,5cis-dicarboxylic acid-1-carboxylate - 18-Crown-6 - Hydrate
C9H11O6,NH4,C12H24O6,H2O
Crystal Growth & Design (2006) 6, 1 32-35
a=25.4695(14)Å b=20.8784(12)Å c=9.6872(5)Å
α=90.00° β=90.00° γ=90.00°
Methylpyrazine dicarboxylic acid
C7H6N2O4
Crystal Growth & Design (2006) 6, 9 1995
a=13.6919(16)Å b=13.6919(16)Å c=21.789(5)Å
α=90.00° β=90.00° γ=120.00°
Methylpyrazine dicarboxylic acid
C7H6N2O4
Crystal Growth & Design (2006) 6, 9 1995
a=13.6937(7)Å b=13.6937(7)Å c=21.345(2)Å
α=90.00° β=90.00° γ=120.00°
Methylpyrazine dicarboxylic acid
C7H6N2O4
Crystal Growth & Design (2006) 6, 9 1995
a=13.6974(6)Å b=13.6974(6)Å c=21.3258(17)Å
α=90.00° β=90.00° γ=120.00°
Lamotrigine cinnamic acid salt cocrystal
C9H7.34Cl2N5,C9H7.66O2
Crystal Growth & Design (2015) 15, 12 5816
a=17.5729(18)Å b=7.8008(8)Å c=14.8637(15)Å
α=90° β=113.662(2)° γ=90°
Lamotrigine-vanilline cocrystal
C9H7Cl2N5,C8H8O3
Crystal Growth & Design (2015) 15, 12 5816
a=10.7918(9)Å b=13.6805(12)Å c=13.8215(12)Å
α=90° β=110.5040(10)° γ=90°
Lamotriginium-salicylate acetonitrile solvate
C9H8Cl2N5,C7H5O3,C2H3N
Crystal Growth & Design (2015) 15, 12 5816
a=8.8408(5)Å b=10.9916(6)Å c=12.1332(5)Å
α=111.359(4)° β=111.196(5)° γ=93.988(5)°
Aceclofenac-piperazine(0.5)-hydrate
C18H20Cl2N2O5
Crystal Growth & Design (2013) 13, 4 1590
a=14.555(4)Å b=14.950(4)Å c=8.557(3)Å
α=90.00° β=92.473(4)° γ=90.00°
Lornoxicam Mesylate salt
C14H14N3O7S3Cl
Crystal Growth & Design (2014) 14, 6 2945
a=13.4730(11)Å b=13.2684(8)Å c=11.2407(8)Å
α=90.00° β=111.707(9)° γ=90.00°
Lornoxicam Piperazine salt
C15H16N4O4S2Cl
Crystal Growth & Design (2014) 14, 6 2945
a=13.2445(9)Å b=13.0698(7)Å c=11.6414(8)Å
α=90.00° β=111.547(8)° γ=90.00°
Lornoxicam Hydrochloride salt
C13H11N3O4S2Cl2
Crystal Growth & Design (2014) 14, 6 2945
a=6.8795(5)Å b=9.1606(8)Å c=26.201(2)Å
α=90.00° β=90.00° γ=90.00°
Clotrimazole-2,5-Dihydroxybenzoic acid
C22H18ClN2,C7H5O4
Crystal Growth & Design (2015) 15, 5 2493
a=10.1762(10)Å b=10.6463(8)Å c=13.0417(9)Å
α=108.469(7)° β=102.963(8)° γ=107.069(8)°
Clotrimazole-Caffeic acid-anisole
C23H17ClN2,C9H7O4,C7H8O
Crystal Growth & Design (2015) 15, 5 2493
a=12.4974(17)Å b=14.527(2)Å c=17.789(2)Å
α=90.00° β=96.028(2)° γ=90.00°
Clotrimazole-2,4,6-Trihydroxybenzoic acid
C22H18ClN2,C7H5O5
Crystal Growth & Design (2015) 15, 5 2493
a=12.0214(14)Å b=13.8128(16)Å c=15.9926(18)Å
α=90.00° β=97.934(2)° γ=90.00°
Clotrimazole-Adipic acid
C22H17ClN2,0.5(C6H10O4)
Crystal Growth & Design (2015) 15, 5 2493
a=8.7300(9)Å b=9.6543(9)Å c=13.2542(13)Å
α=74.480(9)° β=84.281(8)° γ=85.466(8)°
Blonanserinium nicotinate salt
C23H31FN3,C6H4NO2
Crystal Growth & Design (2014) 14, 5 2557
a=12.2184(12)Å b=11.6715(9)Å c=18.5188(17)Å
α=90.00° β=94.867(8)° γ=90.00°
Blonanserinium mesylate monohydrate
C23H31FN3,CH3O3S,H2O
Crystal Growth & Design (2014) 14, 5 2557
a=6.7308(8)Å b=10.5808(13)Å c=34.376(4)Å
α=90.00° β=91.931(2)° γ=90.00°
Blonanserinium mesylate salt
C23H31FN3,CH3O3S
Crystal Growth & Design (2014) 14, 5 2557
a=12.6945(9)Å b=13.7444(9)Å c=14.4954(10)Å
α=98.5020(10)° β=98.8410(10)° γ=105.9490(10)°
Blonanserinium succinate salt
C23H31FN3,C4H5O4
Crystal Growth & Design (2014) 14, 5 2557
a=8.9999(9)Å b=13.0762(13)Å c=21.704(2)Å
α=90.00° β=90.00° γ=90.00°
Blonanserin-suberic acid cocrystal
C23H30FN3,0.5(C8H14O4)
Crystal Growth & Design (2014) 14, 5 2557
a=13.655(12)Å b=11.540(10)Å c=15.669(14)Å
α=90.00° β=103.515(13)° γ=90.00°
Blonanserinium tosylate salt
C23H31FN3,C7H7O3S
Crystal Growth & Design (2014) 14, 5 2557
a=6.3176(9)Å b=36.767(5)Å c=11.6580(17)Å
α=90.00° β=99.549(2)° γ=90.00°
Trimethoprim
C14H18N4O3
Crystal Growth & Design (2015) 15, 4 1745
a=7.9202(8)Å b=10.4378(11)Å c=10.5434(11)Å
α=106.8710(10)° β=101.686(2)° γ=111.8230(10)°
Trimethoprim
C14H18N4O3
Crystal Growth & Design (2015) 15, 4 1745
a=18.250(2)Å b=5.9580(7)Å c=12.7527(14)Å
α=90.00° β=93.969(2)° γ=90.00°
Isoniazid-Ferulic acid
C10H10O4,C6H7N3O
Crystal Growth & Design (2014) 14, 11 5991
a=7.3931(8)Å b=7.5175(10)Å c=15.0471(16)Å
α=82.133(10)° β=77.444(9)° γ=73.205(10)°
Isoniazid-Vanillic acid
C8H8O4,C6H7N3O
Crystal Growth & Design (2014) 14, 11 5991
a=7.3139(5)Å b=7.4461(6)Å c=14.2942(9)Å
α=101.678(6)° β=91.124(5)° γ=109.433(7)°
Isoniazid-Resorcinol
C6H7N3O,C6H6O2
Crystal Growth & Design (2014) 14, 11 5991
a=5.0623(5)Å b=16.119(2)Å c=14.6266(15)Å
α=90.00° β=96.618(10)° γ=90.00°
Isoniazid-Caffeic acid
C9H8O4,C6H7N3O
Crystal Growth & Design (2014) 14, 11 5991
a=7.4051(16)Å b=9.733(2)Å c=10.384(2)Å
α=74.183(3)° β=84.064(4)° γ=78.944(3)°
Isoniazid-Vanillic acid
C8H8O4,C6H7N3O
Crystal Growth & Design (2014) 14, 11 5991
a=25.379(3)Å b=4.9943(6)Å c=22.281(3)Å
α=90.00° β=91.741(12)° γ=90.00°
Acedapsone
C16H16N2O4S
Crystal Growth & Design (2014) 14, 10 5260
a=8.2728(8)Å b=7.8636(8)Å c=23.762(2)Å
α=90.00° β=96.295(2)° γ=90.00°
Acedapsone
C16H16N2O4S
Crystal Growth & Design (2014) 14, 10 5260
a=24.519(3)Å b=8.0444(7)Å c=16.2501(15)Å
α=90.00° β=105.767(2)° γ=90.00°